InsiderTrades

Form 4 for BIIB Biogen

Accepted 2023-09-06 00:00:00 ET · period of report 2023-09-01 · accession 0001127602-23-023824 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-09-06 2023-09-05 BIIB Singhal Priya Head of Development S - Sale+OE $269.43 -431 3,354 -11% -$116.1K
D 2023-09-06 2023-09-01 BIIB Singhal Priya Head of Development F - Tax $267.17 -807 3,785 -18% -$215.6K
D 2023-09-06 2023-09-01 BIIB Singhal Priya Head of Development M - OptEx $0.00 +1,668 4,592 +57% $0
D 2023-09-06 2023-09-01 BIIB Singhal Priya Head of Development M - OptEx $0.00 -1,668 3,337 -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-09-05 S D 431 $269.43 3,354.09 D — —
2 Common Common Stock 2023-09-01 F D 807 $267.17 3,785.09 D — —
3 Common Common Stock 2023-09-01 M A 1,668 $0.00 4,592.09 D — —
4 Derivative Restricted Stock Unit 2023-09-01 M D 1,668 $0.00 3,337 D $0.00 · — to 2025-09-01 1,668 Common Stock (F1) This award was granted to the reporting person on September 1, 2022 and will vest in three equal installments on each anniversary of the grant date.